SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is soaring after pre-announcing preliminary Q3 revenue well above expectations and reiterating robust fiscal year growth, fueling strong community belief that the AI data center infrastructure play was significantly undervalued amid massive hyperscaler capital expenditure. Traders are actively discussing the stock's sharp rebound and its potential for continued upside as a key beneficiary of the ongoing AI buildout.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin (BNKR) is seeing significant trending activity with its community actively working to "drop a zero" from its price, driven by excitement over its AI-powered utility, new exchange listings, and ecosystem expansion on the Base chain. Community members are enthusiastically accumulating, citing its undervalued market cap and growing revenue, even amid broader crypto market volatility.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending following a drastic stock plunge driven by the abrupt departure of its CFO and general counsel, an SEC investigation into cash management, and an accounting review exposing internal control weaknesses and revised future guidance, sparking intense community debate between those foreseeing catastrophe and others viewing it as an extreme overreaction and buying opportunity.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending following the FDA's issuance of a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns with trial design and the appropriateness of its surrogate endpoint. The community is actively debating the broader implications for gene therapies, RGNX's financial outlook, and potential impacts on its Duchenne and AbbVie-partnered programs.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

MSLE is actively discussed following its recent NASDAQ listing, a reverse split, and a substantial equity raise. While optimists view the financing as a strong vote of confidence in its "revolutionary" muscle regeneration drug for Duchenne patients and foresee potential acquisition, skeptics caution about dilution and characterize early clinical data as premature hype.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is seeing significant conversation after its CEO signaled multi-year highs in mortgage loan production and gain-on-sale performance, leading to community debate on whether its integrated platform can overcome broader housing market headwinds amidst ongoing institutional accumulation.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health (OSCR) is trending sharply higher after the House passed a bill to extend ACA subsidies, fueling investor optimism for significant upside and a potential short squeeze, though community debate persists on the bill's Senate fate and the company's path to profitability ahead of its upcoming earnings.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending as its S-4 registration for the Infleqtion merger is effective, with a shareholder vote scheduled for February 12 and a ticker change to INFQ expected by February 17. The community actively debates Infleqtion's perceived undervaluation compared to quantum peers, highlighting its neutral-atom technology, existing revenue, and strategic partnerships with government agencies and NVIDIA, while also discussing recent volatility and concerns about potential post-merger dilution.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively discussed as the community awaits crucial R2 SUV details and earnings, with its CEO emphasizing the R2's cost-efficient design and potential to significantly boost profitability, though investor sentiment remains divided on its market impact and the company's cash burn amid EV sector competition.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is experiencing extreme volatility following a patent infringement lawsuit from Novo Nordisk and FDA scrutiny regarding its compounded semaglutide weight-loss pill, which the company has now ceased offering. The community is fiercely debating whether this represents a fundamental threat and further downside, or an overreaction presenting a significant short squeeze opportunity for a company with strong core business segments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immix Biopharma (NASDAQ:IMMX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised Immix Biopharma from a "sell" rating to a "hold" rating in a research report on Saturday...

Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities

Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement.read more...

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 27.5% in December

Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 1,746,822...

Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded Immix Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday...

FY2025 EPS Estimates for Immix Biopharma Lifted by Analyst

Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 earnings estimates for Immix Biopharma in a research report issued on Tuesday...

<ul class="summary-bullets"><li>US equities look to extend last week’s gains.</li><li>Market-based odds now show an 87% chance of a rate cut.</li><li>Retail sentiment on Stocktwits, however, remains bearish on SPY and QQQ.</li></ul>U.S. stock futures inched higher in early Monday trade, as the market looks to build on gains from the previous week. All eyes will be on the highly anticipated Federal Reserve policy statement and press conference later in the week.&nbsp;According to the<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">&nbsp;CME FedWatch tool</a>, the market is now pricing in an 87% chance of an interest rate cut this Wednesday, sharply higher than the 66% bets a month earlier.As of 3:00 a.m., ET on Monday, the Nasdaq 100 futures and S&amp;P 500 futures were up 0.2%, the Russell 2000 futures gained 0.3%, while the Dow futures were flattish with a positive bias. On Stocktwits, however, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and that toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq 100 Index, remained ‘bearish’ early Monday.&nbsp;<h2 class="st-heading-2">Stocks On Trending Watchlist&nbsp;</h2>Netflix (NFLX) and Warner Bros Discovery (WBD)&nbsp;remain in focus following the massive M&amp;A deal and potential regulatory overhang, including concerns raised by&nbsp;U.S. President Trump.Confluent (CFLT) is trending amid <a href="https://stocktwits.com/news-articles/markets/equity/why-ibm-may-want-confluent-3-charts-reveal-ai-play-s-promise/cLIYjkHREll">reports</a> of a potential&nbsp;$11-billion acquisition by IBM.&nbsp;Boeing (BA) is seeing retail chatter due to the impending close of the Spirit AeroSystems deal.Workhorse (WKHS)&nbsp;is on traders’ radar ahead of a 1-for-12 reverse split that takes effect on Dec 8.&nbsp;Eli Lilly (LLY), Pfizer (PFE), and Johnson &amp; Johnson (JNJ) have secured spots on China's drug catalog, with a total of 19 medicines making the list, according to a Bloomberg report.&nbsp;Immix Biopharma (IMMX) has priced an $100 million public offering via common stock and warrants, mainly to finance the development of its drug NXC-201.Oracle (ORCL) gains traction ahead of its earnings release on&nbsp;Dec. 10.&nbsp;Coreweave (CRWV) is also on the retail radar.&nbsp;Other companies reporting earnings this week are Adobe (ADBE), Broadcom (AVGO), Costco (COST), and Lululemon (LULU).<h2 class="st-heading-2">Key Catalysts To Watch Out For</h2>On the economic front, the big market mover will be the upcoming Fed meeting on December 9-10. No major data is scheduled&nbsp;for release today.&nbsp;And on the earnings front, investors will be watching for Toll Brothers, AlphaTON Capital, among others.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Nasdaq, S&P 500 Futures Rise Ahead Of Fed Decision This Week: Why NFLX, CFLT, BA, LLY, IMMX Are On Traders' Radar

Market-based odds now show an 87% chance of a rate cut.

Equity

Immix Biopharma (NASDAQ:IMMX) Trading 4.5% Higher - What's Next?

Immix Biopharma (NASDAQ:IMMX) Shares Up 4.5% - What's Next...

HC Wainwright Reduces Earnings Estimates for Immix Biopharma

Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Research analysts at HC Wainwright cut their FY2025 earnings per share (EPS) estimates for shares of Immix Biopharma in a research report issued on...

Immix Biopharma (NASDAQ:IMMX) Announces Earnings Results, Misses Expectations By $0.05 EPS

Immix Biopharma (NASDAQ:IMMX - Get Free Report) announced its quarterly earnings data on Friday. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate...

Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Current Price	$6.42
Prev Close	$6.74
Open	$6.90
Dividend Yield	0.00%
50-Day Moving Average	$5.44
Beta	1.28
Avg. Volume	1.01M
PE Ratio	-8.57

52-Week High	$7.73
52-Week Low	$1.34
Market Capitalization	$357.41M
EPS (Annual)	-$0.7641
Price to Book	26.94
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

IMMX
Immix Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IMMX News

IMMXImmix Biopharma Inc